

Index

Note:

All index entries relate to NPH unless otherwise stated.
 vs denotes differential diagnosis, or comparisons.

Abbreviations:

CBF –cerebral blood flow
 ETV –endoscopic third ventriculostomy
 NPH –normal pressure hydrocephalus
 PTCS –pseudotumor cerebri syndrome
 SAH –subarachnoid hemorrhage
 SHYMA –syndrome of hydrocephalus in young and middle-aged adults

abdominal shunt, CT, 114, 116

abdominal X-ray, 110, 111

acetazolamide, 261, 294, 300

acquired hydrocephalus, 36, 38
see also idiopathic NPH (iNPH)

adolescents, care transitioning, 265, 266–267

age/aging (hydrocephalus and), 16–17, 283

blood and CSF flow, 127
 experimental animals, 29

iNPH and, 59, 207

SHYMA, 247–248

see also elderly

aleuronate granules, 31

Alzheimer's disease (AD), 71, 101

biomarkers, 101, 164, 165

cognitive dysfunction, 72, 101

iNPH differential diagnosis, 77, 103

biomarker use, 165–167, 169

neuropsychological deficits, iNPH vs, 74

NPH coexistence, 16–17, 71, 76, 101
 case study, 108

urinary incontinence, 80, 81

amyloid, soluble precursor protein (sAPP), 166, 168, 169

amyloid beta protein, as iNPH biomarker, 164, 169

Alzheimer's disease vs, 165, 166, 169

Parkinson's disease vs, 168

prognostic biomarker, 168, 169

amyloid plaques, 165

anatomy, CSF system, 1–2

spinal, 3

animal models (hydrocephalus), 28–33, 48

animals used, 30

classification, 30

CSF shunting techniques, 33

ethics, 28–29

EU legislation, 28

existing/preferred (for hydrocephalus), 30–32

genetically determined, 32

physical/chemical agents

inducing, 31, 33

formal (general)

requirements, 29–30

genes for hydrocephalus, *see* genes/loci

genetic models, *see* genetic models

interstitial edema (brain), 71

NPH, 33

principles (ethical), 28–29

questions needing clarification, 30

recent/current research areas,

32–33, 48

requirements/challenges, 30

validity evaluation, 29–30

see also experimental

hydrocephalus

animal(s), naturally occurring

hydrocephalus, 30, 31

antibiotic(s)

intravenous, in shunt infections,

186–187

perioperative, 186

prophylactic, for ETV, 224

antibiotic-impregnated shunts (AIS), 186, 213

costs and cost/benefits, 215

decreased infection rates, 213–214

pathogens/infections despite,

214–215

antisiphon devices (ASD), 176,

193–194, 241

external pressure effect, 199

indications and functions, 176

membrane construction, 194

positioning, 176

types, 193–194

Apaf1 protein, 46

ApoE e3 allele, 38

ApoE e4 allele, 38

apoptotic pathways, disrupted, 46

aquaporin(s), 6–7, 8

aquaporin-1 (AQP1), 6, 8, 46

knockout (KO) mice, 7

pathophysiological role, 46

aquaporin-1 channel, 4, 46

aquaporin-4 (AQP4), 6, 7, 8, 46

astrocytic endfeet, 6, 7

knockout mice/deficiency, 7, 32, 46

up-regulation/increased, 46

aqueductal stenosis, *see under* cerebral aqueduct (of Sylvius)

arachnoid barrier cells, 6

arachnoid cell layer, 5–6

arachnoid cyst, 275

cerebellar, NPH with, 279–280, 283

in elderly, 275, 279–280, 283

giant suprasellar, in fetus, 282

management, 285, 286

multiple, hydrocephalus

management, 281

posterior fossa, 276–277

arachnoid fibrosis, 14

arachnoid granulations, 8–9

anatomy, 8–9

CSF reabsorption, 8,

150, 296

in PTCS, 296, 299, 300

in newborn infants, 219

spinal, CSF drainage, 10

arachnoid trabecular cells, 6

arachnoid villi, 8, 9, 150

arterial blood flow energy, CSF

pulsation and, 10, 71

ASPP2, and ASPP2, 46

astrocytes, reactive, 23

astrocytoma, 250

asymptomatic ventriculomegaly,

see ventricular enlargement,

asymptomatic

atrial catheter insertion, 180–182

complications, 181

procedure, 181

Index

- atrial pressure, right, 294
 attention deficit, 73–74, 76
 attention deficit hyperactivity disorder (ADHD), 277–278
 autoregulation, cerebral, 159–160
 autosomal dominant inheritance, 38
 autosomal recessive congenital hydrocephalus mice, 39–40
 autosomal recessive hemorrhagic hydrocephalus (hhy) mouse, 40
 autosomal recessive hydrocephalus with hop gait (hyh) mouse, 40
- B waves, 70, 154–155, 159
 B9d2 protein, 46
 balance, grading scale, 95, 240
 balance control, 63, 67
 impaired, gait dysfunction, 67
 bariatric surgery, 294, 301
 Barthel ADL Index, 242
 basilar artery, in ETV, 224, 225
 “bedside to bench” concept, 29
 behavioral outcome, congenital hydrocephalus, 272
 bioactive peptides, 5
 biofilm, 186, 213
 biomarkers (CSF), 164–170
 Alzheimer’s disease, 101, 164, 165
 CSF sample requirements, 170
 definition, 164
 experimental problems, 169–170
 idiopathic NPH
 Alzheimer’s disease vs, 165–167, 169
 historical perspective, 164, 170
 Parkinson’s disease vs, 167–169
 rationale for use, 164–165
 summary of current evidence, 169
 vascular dementia vs, 167
 prognostic, 165, 168–169
 study requirements and limitations, 170
 Black outcome scale, 242
 Black’s classification, 91, 93
 bladder (urinary), 82
 contraction, control, 82
 filling, sensation, 23
 overactive, 81, 82, 84, 85
 sensation, terminology, 83
 Blake’s pouch cysts, 286–287
 blood flow, cerebral, *see* cerebral blood flow
 blood–brain barrier, aquaporins role, 7
 body position, *see* posture
 brain
 atrophy, 147, 158, 159
 damage, pathogenesis in NPH, 15
 equilibrium pressure, 126
 sagging, in intracranial hypotension, 257, 258–259
 tumors, 102, 248–251
 volume, 1
 water distribution, 1
 burr holes, for ETV, 224, 225
- carbon dioxide (CO₂) reactivity, 160
 carcinomatous meningitis, 249
 cardiac cycle
 CSF and blood flow interactions, 126, 129
 CSF flow affected by, 5, 6, 71, 124, 128, 150
 CSF flow parameters, 124
 temporal normalization of PC-MRI, 124
 Windkessel effect, 10, 153, 154
 intracranial pressure fluctuations, 127–128, 152
 intracranial volume change, 128
 cardiac gating, MRI, 121–122
 cardiac pulsation, recording (ECG, plethysmography), 121–122
 caregiver burden, urinary incontinence and, 80, 85
 caregiver burden scale, 94
 case studies, 105, 106, 108
 see also management, of hydrocephalus in CSF pathologies
 caspases, 46
 caudate nucleus, 68
 CD68, 47
 CDO protein, 47
 cerebellar arachnoid cyst, NPH with, 279–280, 283
 cerebellar herniation, 291
 cerebellar tonsils, 291
 cerebral aneurysms, 60, 251, 252
 cerebral aqueduct (of Sylvius), 1
 anatomy, 2
 closure, Chiari II malformation and, 292
 defective development, 40
 fast CSF flow-induced artifact (flow void), 121, 133
 flow normalization, cognition improvement, 73
 hyperdynamic CSF flow, 71
 MRI scans, 114
 obstruction, 17
 secondary closure in development, 46, 292, 293
 stenosis, 17, 40, 45, 130
 ETV outcome, 218, 219, 227
 HTX and LEW/Jms rat models, 40, 44
 incomplete, PC-MRI, 130
 late-onset idiopathic, 247–248
 in LOVA, 247–248
 PC-MRI, 115–117, 130–131
 stroke volume in NPH, 285
 subcommissural organ role, 40
 cerebral autoregulation, 159–160
 cerebral blood flow (CBF), 23, 125, 160–161
 arterio-venous flow difference, 126–128
 CSF flow and, *see* cerebrospinal fluid (CSF) flow
 experimental hydrocephalus, 15
 global decrease, iNPH mechanism, 71, 72
 healthy vs NPH patients, 127
 hypoperfusion, NPH and, 15, 23, 127, 160
 inflow calculation, 126
 mean, normal, 126, 127
 pulsation, disorder, 154
 regional, 160
 decrease, effects, 68, 71
 shunting effect, 160–161
 in white matter, 160, 161
 cerebral blood pressure, 147
 cerebral convexity CSF spaces, 3
 cerebral edema, 71, 299
 cerebral elasticity, 152
 cerebral vein, engorgement, 257
 cerebral venography, retrograde, 300
 cerebral venous narrowing, PTCS, 299–300
 cerebral venous outflow, 126, 133
 cerebrospinal dynamic compensation, law, 152
 cerebrospinal fluid (CSF), 2, 139–147
 absorption/reabsorption, 8, 14, 139, 143, 150, 151, 299
 arachnoid villi, 8, 9, 14
 cerebral autoregulation and, 159
 lymphatic drainage, 9–10
 pressures, 141
 production balance, 139, 151
 production imbalance, 72, 130
 in PTCS, 296, 299
 rate, 140
 spinal lymphatics, 9–10
 Windkessel effect, 10
 biomarkers, *see* biomarkers (CSF)
 circulation/flow, *see* cerebrospinal fluid (CSF) flow
 cleansing role of choroid plexus, 5, 16
 composition, 1, 31, 299
 density, 1
 diversion, *see* shunt(s); shunting
 drainage (normal), *see* cerebrospinal fluid (CSF), absorption/reabsorption
 drainage (surgical), *see* shunt(s); shunting

Index

- dynamics, 139–141, 150–152, 176, 190
 applications, 150
 B wave assessment, 154–155
 brain atrophy, 158, 159
 cerebrovascular pressure
 reactivity (PRx), 155–156
 infusion tests, 155–156
 long-term shunts, 269
 normal, 159
 pathophysiology not
 correlated, 285
 in persistent symptoms, 190
 quantitative assessment, 150–161
 shunt indication, 159, 190, 284, 285
 shunts effect on, 191
 unpredictable nature, 283
see also specific parameters
- fistulae, 256
 functions, 1, 14, 71, 128, 150
 hypovolemia, pathogenesis, 256
 leaks, 256–262
 detection, 262
 diagnostic criteria, 259–260
 etiology, 256
 ETV complication, 227
 imaging, *see under* intracranial
 hypotension, spontaneous
 management and outcome, 261–262
 pathogenesis, 256
 spinal, headaches, 257
see also intracranial hypotension, spontaneous
- opening pressure, 259
 outflow resistance, 139, 143, 146
 R_{out} , *see* R_{out} (CSF outflow resistance)
 physiology, NPH differential
 diagnosis, 103–104
 pressure–volume compensation, 150–152
 pressure–volume compensatory
 reserve, 155, 158–159
 pressure–volume curve, 139–140
 production and rate of, 1, 3, 14, 139, 150
 average rate, 143, 204
 choroid plexectomy effect, 8
 choroid plexus role, 4, 128
 clearance balance, 139, 151
 clearance imbalance, 72, 130
 drugs reducing, 4
 excess, pseudotumor cerebri, 299
 increased, in tumors, 249
 interstitial fluid role, 3, 5
 measurement, 144
 reduced, toxin accumulation, 71, 72
 protein, 1
- pulsation, 5, 10, 150, 220
 pulsation energy, dissipation, 10, 71
 pulse pressure, 147
 pulse pressure amplitude,
 monitoring, 146
 replacement, hypovolemia, 261
 rhinorrhea, 297
 secretion, 4, 139
 shunting, *see* shunt procedures;
 shunting
 siphoning into distal
 compartment, 176
 storage rate, 140, 151, 152
 stroke volume, 124, 125, 128, 133, 285
 turnover, aquaporins and ion
 channels, 6–8
 ventricular pulsation amplitude, 154
 volume, 1, 128
- cerebrospinal fluid (CSF)
 disorders, 275
 cerebrospinal fluid (CSF) flow, 3, 5, 139, 150, 191
 aquaporins role, 6, 46
 blood flow interaction, 125–129, 133
 arterio-venous flow difference, 126–128
 cardiac cycle effect, 126, 129, 128
 healthy adults, 126–129
 protocol, regions explored, 126
 cardiac cycle affecting,
 see cardiac cycle
 cells influencing, 5
 cervical vs ventricular, 126, 133–134
 Chiari malformation, 135, 134
 curve, PC-MRI, 125
 electrical model, 139, 141, 151, 191
 healthy vs NPH case, 132, 133–134
 hydrocephalus with CSF
 pathologies, 275
 hyperdynamic, 71, 133
 imaging, 121–136
 flow parameters, 124
 flow rate estimation, 124
 inflow/outflow artifacts, 121, 133
 MRI, before ETV, 223–224
 MRI impact, 285
 temporal normalization, 124
 time-of-flight MRA, 121
 see also phase-contrast MRI (PC-MRI)
- imaging of disorders, 129–134
 after ETV, 131, 131
 aqueductal stenosis, 130–131
 Chiari malformation, 135, 134
 NPH, 129–134
 syringomyelia, 135
 impairment, causes, 6, 14
 mechanisms and models, 150–152
 normal, dynamics, 159
- oscillation quantification, 127, 128, 131, 133
 outflow resistance, infusion test, 103
 perivascular, 6
 posterior fossa cyst without
 hydrocephalus, 277
 pulsatile, 5, 10, 150, 220
 rate, diagnosis of NPH, 131–133
 rate estimation, 124
 regulation, 125
 routes, 1–2, 6–8
 spinal, 6
 subarachnoid cisterns, 5–6
 through ventricles, 5
 venous sinuses, 9
 Virchow–Robin spaces, 5–6
 vascular components, 159
 cerebrospinal fluid (CSF) spaces, 1–3, 285
 cerebral convexity, 3
 spinal, 3
see also cisterns (subarachnoid);
 subarachnoid space (SAS);
 specific ventricles
- cerebrospinal fluid (CSF) system, 1–10
 anatomy, 1–2
 spinal, anatomy, 3
see also cerebrospinal fluid (CSF) spaces
- cerebrovascular disease, 15–16, 17, 101
 cerebrovascular pressure reactivity (PRx), 155–156
 Certas valve, 196
 cervical lymphatics, 9
 cervical spondylotic myelopathy, 101
 chest ultrasound, 112
 chest X-ray, 110, 111, 177
 Chiari I malformation, 277–278, 284, 285, 291
 anatomy, 291
 benign intracranial hypertension, 294–295
 decompression, 292, 294
 description/features, 291–292
 hydrocephalus relationship, 292
 management, 278, 279, 283
 prenatal surgery, 286
 pseudotumor cerebri and, 294–295
 Chiari II malformation, 291–294
 Chiari malformation, 291–295
 adult, *see* Chiari I malformation
 CSF flow, 135, 134
 types, 291
- children
 closed fontanelle, ventricular
 catheter insertion, 179
 ETV in, 218–219, 222
 PTCS in, 297
 shunt infection rates, 212

Index

- choroid plexectomy, 8
 choroid plexus, 2, 4–5
 CSF production/secretion, 3, 4, 128
 PTCS pathophysiology and, 299, 300
 functions, 4, 5
 ion channels and CSF turnover, 7
 structure, 4
 tumors, 249, 251
 chromosome 8q12–2–q21.2
 microdeletion, 38
 chromosome 19q12–13.31, 38
 chronic subdural hematoma, 102
 cilia, 5, 44
 receptor signaling, defects, 45–46
 ciliopathies, 44–46
 cisterns (subarachnoid), 1, 3
 anatomy, 3, 223
 CSF flow, 5–6
 CSF flow blockage, 6, 220
 classification (human hydrocephalus), 36, 91, 287
 based on symptomatology, 104
 CSF pathologies with, 286–287
 see also grading scales (NPH)
 closing pressure, 196
 Codman Certas Valve, 199
 Codman Hakim Adjustable Valve, 176, 194, 196, 199–200
 cognitive changes, 23
 cognitive function, in walking/
 gait, 65–66
 cognitive impairment (in CSF
 pathologies), 285
 cognitive impairment (in iNPH),
 72–73, 101–102
 adolescents/young adults, 266
 CSF drainage effect, 75–77
 differential diagnosis, 101–102
 evaluation, 72, 73, 95, 101, 284–285
 iNPH scale, 239, 284–285
 patient selection, outcome
 improvement, 233, 242,
 284–285
 features, 72–73, 74, 77, 99, 284–285
 grading, *see* grading scales (NPH)
 pathophysiology, 70–77
 putative pathogenic
 mechanisms, 70–72
 see also under pathophysiology
 (of iNPH)
 transitional care (pediatric to
 adult), 265
 see also dementia;
 neuropsychological deficits
 (in iNPH)
 communicating hydrocephalus, 190,
 220–221
 choroid plexus tumors and, 249
 CSF dynamics, 159, 220–221
 ETV in, 218–222, 304
 experimental, 31, 33
 intracranial CBF pulsation disorder,
 154, 220–221
 pathogenesis, 3, 6
 shunt type, 185
 comorbid diseases, 76, 77, 100, 304
 Alzheimer's disease, *see* Alzheimer's
 disease (AD)
 biomarker use in, 165, 170
 cerebrovascular disease, 15–16,
 17, 101
 grading scales and, 94, 96
 impact on NPH outcome, 244
 VP shunt complications, 210
 comorbidity index, 94, 96, 244
 compensated hydrocephalus, 247, 248,
 292, 293
 compliance, 125, 133, 152
 decreased, communicating
 hydrocephalus, 220–221
 decreased in prolonged shunting,
 269, 270
 see also normal volume
 hydrocephalus (NVH)
 definition, 139–140
 compliance curve, 139–140
 computed tomography (CT), 103,
 110–114
 abdominal shunt evaluation,
 114, 116
 chest, 115
 CSF leak, 257
 diagnosis of NPH, 110–113, 113
 postoperative management,
 113–114
 pre- vs postoperative image
 comparison, 113, 114
 pseudotumor cerebri syndrome, 298
 risks, 114
 shunt assessment, 209
 shunt malfunction detection,
 113–114, 115, 116
 ventricular catheter insertion, 179
 ventriculoperitoneal shunt, 209
 volumetric analysis by, 113
 computed tomography (CT)
 venography, 298, 299
 computerized infusion test, 155–156
 congenital hydrocephalus, 36
 adult hydrocephalus differences, 265
 clinical outcome, 271–272
 complications/morbidities, 271–272
 education and employment, 272–273
 epidemiology, 38, 57
 etiologies, 264
 genetic epidemiology, 37
 genetics, and inheritance, 38–39
 monogenic (animal models), 39–40
 neuropsychological outcome,
 272–273
 pathophysiology,
 see pathophysiology,
 genetic basis
 recurrence risk ratios (RRRs), 37
 risk rates, 38
 shunt independence, 267–269
 see also endoscopic third
 ventriculostomy (ETV)
 transition of care (to adult centers),
 see management
 twin studies, 36–37
 uncomplicated (third ventricle
 obstruction), 38
 X-linked, 38
 congenital malformations,
 prevalence, 57
 connective tissue disorders, 256
 constant flow infusion method,
 144–145
 constant pressure infusion method, 145
 construct validity, animal models, 29
 continuous spinal/ventricular
 drainage, 103
 cooperative studies, differences,
 grading scale role, 96
 core imaging, 103, 110–119
 corpus callosum, 15, 17
 cortical dysfunction, gait dysfunction
 theories, 65–66
 cortical-subcortical circuit defects, 67
 corticobasal degeneration, 102
 cranial compartments, 125, 128–129
 craniosynostosis, 270
 Creutzfeldt–Jakob disease (CJD), 102
 cribriform plate, 9
 CYP2J2 transgene, 44
 Dandy criteria, 292, 296–297
 Dandy–Walker cyst, 286–287
 Davson's equation, 299
 DBI (GABA_A receptor modulator), 48
 deep white matter ischemia (DWMI),
 240–241
 dementia
 Alzheimer's, *see* Alzheimer's
 disease (AD)
 dual-tasking and gait
 dysfunction, 66
 falls, 81
 frontotemporal, 101–102, 106
 grading scales, iNPH, 92
 iNPH differential diagnosis, 77,
 99, 101
 iNPH epidemiology, 59
 multi-infarct, 80, 81
 in NPH, assessment, 92
 NPH outcome, 244
 post-stroke, 80

Index

- urinary incontinence, 80–81
- vascular, 101, 167
- see also* cognitive impairment (in iNPH)
- dementia with Lewy bodies (DLB), 101, 102
- depression, 101, 272
- DESH, 99, 115, 117, 233, 304
- detrusor overactivity, 85–87, 102
- shunt surgery results, 87–88
- development
 - abnormal, hydrocephalus pathophysiology, 48, 275
 - CSF and blood flow, 125
 - early, enhanced gene expression, 47–48
 - loss of molecular cues during, 40–46, 47
- developmental delay, 264, 266
- diagnosis (of NPH), 99–104
 - criteria in iNPH, 59
 - delay in, 100, 104
 - difficulties, 60–61, 99, 100
 - imaging, *see individual imaging modalities*
 - infusion tests, *see* infusion techniques/tests
 - iNPH, for outcome improvement, 232–233
 - lack of awareness reducing, 60–61, 99, 100, 104, 215
 - neurological examination, 99–100
 - universal criteria, lack of, 61
 - see also* differential diagnosis (of NPH)
- diagnostic work-up, 100–101
- DIAPPER mnemonic, 82
- diaschisis, 72
- differential diagnosis (of NPH), 76–77, 99–104, 207
 - Alzheimer's disease, *see* Alzheimer's disease (AD)
 - case studies, 105, 106, 108
 - dementia syndromes, 77, 99, 101–102
 - by imaging, 102–103, 233
 - iNPH, 233
 - Parkinson's disease vs, biomarkers, 167–169
 - by pathology, 169–170
 - R_{out} use, 158
 - by symptoms
 - cognitive impairment, 101–102
 - gait dysfunction, 100–101
 - urinary dysfunction, 81–82, 102
 - vascular dementia, biomarkers, 167
- disproportionately enlarged subarachnoid space hydrocephalus (DESH), 99, 115, 117, 233, 304
- Dlg5 protein, 44
- dopamine, 23
- dopamine D2 receptor, hypoactivity, 23, 68
- dopamine signaling abnormalities, 68
- dual-tasking, gait dysfunction, 66, 67
- duplex ultrasound, 110, 112, 181
- dural sinus pressure, 141, 143
- Dutch NPH Scale, 242
- dynein, 45
- education, congenital hydrocephalus, 272–273
- Eide's classification, 91, 93
- elastance coefficient (elasticity), 158, 159
- ELD, *see* external lumbar drainage (ELD)
- elderly
 - arachnoid cyst and hydrocephalus, 275, 279–280, 283
 - case study, NPH diagnosis, 108
 - iNPH symptoms, 61, 100, 147
 - NPH and cerebrovascular disease, 15–16
 - NPH prevalence, 59, 104, 207
 - symptom onset, pathogenesis, 15
 - urinary tract symptoms, 82
- electrical circuit analogy, CSF circulation, 139, 141, 151, 191
- electrocardiography (ECG), 121–122
- En1 (Engrailed 1)*, 47
- En2* gene, 47
- endoscopic third ventriculostomy (ETV), 218–228, 268, 304
 - adult patients, 218, 268
 - advantages/disadvantages, 222, 267
 - anatomic eligibility, 222–224
 - cerebral blood flow, 126
 - in children (age/etiology-dependence), 218–219, 222
 - communicating hydrocephalus, 218–222, 228, 304
 - complications, 226–227, 268–269
 - frequency and type, 269
 - contraindications, 223, 268
 - CSF flow, 126, 222
 - PC-MRI, 131, 223–224
 - CSF leaks after, 227
 - endoscope size, 222–224
 - failure, 225, 227, 268–269
 - causes/risk factors, 222, 268
 - diagnosis, 221–222
 - management, 222, 268
 - timing, 222, 227, 268, 269
 - failure rates
 - adult patients, 218
 - previously shunted patients, 220
 - young infants, 219
 - grading system for eligibility, 223
- hemorrhage and vascular injuries, 226–227
- hypothalamic disorders after, 227
- indications, 218–221, 268, 285
 - hydrodynamic concept and, 220–221
- iNPH, 220–221
- navigation systems, 223, 224
- obstructive hydrocephalus, 218, 219, 221
- outcome, 304
 - children, 218–219
 - factors influencing, 218
 - iNPH, 220, 221
 - intraoperative factors affecting, 221
 - nonobstructive hydrocephalus, 218, 220, 222
 - obstructive hydrocephalus, 218, 227
 - post-hemorrhagic hydrocephalus, 268
 - previously shunted patients, 219–220, 268
- patency, MRI/PC-MRI detection, 117, 131, 223
- postoperative care and follow-up, 227–228
- preoperative planning, 222–224
- repeated, 219, 222
- stoma obstruction, 221, 222, 225, 227
- stoma size, 221
- success, definition of, 221–222
- surgical technique, 224–226
 - ventricular reservoir placement, 225
 - ventricular bowing for, 218
 - ventriculoperitoneal shunt vs, 222
- energy transfer, Windkessel effect, 10, 153, 154
- ependymal cells, 5, 44
 - atrophy, ventricular enlargement causing, 15
 - cilia and ciliopathies, 44–46
- ependymoma, 250
- epidemiology (of hydrocephalus), 57–61, 207
 - age relationship, 59, 207
 - congenital and infantile hydrocephalus, 57
 - genetic, *see* genetic epidemiology
 - idiopathic NPH, 57–60, 104
 - incidence/prevalence of NPH (unclassified), 58, 59, 207
 - shunt insertion criterion, 59
 - secondary NPH, 60
 - summary of studies, 58
 - surgery frequency, 60–61
- epidural blood patch, 261

Index

- essential tremor-idiopathic NPH (ETINPH) disorder, 38
 ethics, animal models, 28–29
 etiology of hydrocephalus, 36, 103, 190, 264, 275
 ETV success score (ETVSS), 223
 Evans ratio, 111, 113
 executive function, in gait, 65–66
 impaired, 66, 73–74
 experimental hydrocephalus
 cerebral blood flow changes, 15
 obstructive, kaolin injection and, 31, 33
 physical/chemical agents inducing, 31, 33
 see also animal models
 external lumbar drainage (ELD), 145–146
 biomarkers as prognostic indicator for, 168
 cognitive and gait response to, 75
 outcome in iNPH, prediction, 233
 shunt responder prediction, 146
 external ventricular drain (EVD), 252, 269, 270
 extracellular fluid, 16
 extracellular space, enlargement, 16
 FAC gene mutation, 37
 falls, 81
 familial hydrocephalus, 36, 37, 38
 see also genetics (of hydrocephalus)
 Fas, 46
 FGFR3, 46
 fibrin sealant, 261
 “fifth ventricle”, 204
 fine motor coordination deficits, 75
 flow–pressure test, 195, 197
 flow-regulating antisiphon devices, 194
 follow-up, 207–215
 ETV, 227–228
 idiopathic NPH, 232, 243
 time frame, 243
 foramen magnum, 291
 foramen of Luschka, 2
 foramen of Magendie, 2
 foramen of Monroe, 1, 2
 forkhead genes, 40
 fornix, of brain, atrophy, 15
 fourth ventricle, 1
 anatomy, 2
 cellular composition, 5
 compensated hydrocephalus, 293
 occlusion of outlet foramina, 292, 293
 small, 247
 FOXC1 gene, 38, 40
 frontal lobe defects, gait dysfunction, 66, 67
 frontotemporal dementia (FTD), 101–102, 106
 gait, 65–66
 in SHYMA, 248
 speed, 66, 92
 gait dysfunction in NPH, 63–68, 81
 characteristic features, 63, 64, 99, 100, 167
 CSF drainage improving, *see* shunting
 diagnosis of NPH, 100–101
 differential diagnosis of NPH, 100–101
 evaluation, 92, 100, 242
 iNPH MCV scale, 241
 iNPH scale, 239
 patient selection and outcome, 233
 grading, *see* grading scales (NPH)
 neurodegenerative disease similarity, 64–66, 100–101, 167
 objective measures, 63–64
 older theories on, 63
 pathogenesis, 23
 presenting symptom, 63, 100
 tentative theories on
 pathophysiology, 63, 64–68
 see also midbrain, diameter
 gender, experimental animals, 29
 genes/loci, 36, 39
 animal models (summary), 41
 FOXC1 and ch mouse, 40
 hhy mouse, 40
 HTX rat model, 39
 human hydrocephalus (summary), 39
 hyh gene (α -SNAP), 40
 mouse models, 39
 transgenic mouse OVE459, 39
 see also pathophysiology, genetic basis
 genetic epidemiology, 36–37
 see also genetics (of hydrocephalus)
 genetic models, 39–40
 enhanced expression of genes, 47–48
 inbred strains/genetic manipulation, 32
 monogenic congenital hydrocephalus, 39–40
 mutant genes, *see* genes/loci
 quantitative trait locus (QTL), 39
 genetics (of hydrocephalus), 36–48
 congenital hydrocephalus, 38–39
 essential tremor-idiopathic NPH disorder, 38
 idiopathic NPH, 38
 loci/genes associated, *see* genes/loci
 maternal component, 37
 pathophysiology, *see* pathophysiology, genetic basis
 see also genetic epidemiology
 giant retrocerebellar cysts, 286–287
 giant suprasellar arachnoid cyst, 282
 gky mouse, 45
 Gli1 and Gli3 proteins, 45
 glucocorticoids, 300
 grading scales (NPH), 91–96, 104
 caregiver burden, 94
 comparisons between, 96
 for ETV eligibility, 223
 general activity, 91, 92
 iNPH, for outcome improvement, 233–240, 242–243
 requirements, types and criticisms, 91
 symptomatology assessment, 91–93, 242–243
 balance, 95, 240
 Black’s classification, 91, 93
 comorbidity, 94, 96
 dementia, 92
 Eide’s classification, 91, 93
 gait, 94, 233, 239, 241, 242
 Hellström’s classification, 92, 94
 INPH scale, 239, 240, 242–243
 Krauss’s classification, 91, 93
 Kubo’s scale, 92, 94, 233–240
 neuropsychological, 72, 73, 95, 239, 284–285
 for outcome assessment, 233–240
 qualitative, 91–93
 qualitative with quantitative, 92–93
 quantitative, 91, 92
 semiquantitative, 92
 urinary incontinence, 92, 95, 240
 gravitational antisiphon devices, 194
 gray matter, distortion and cognitive defects, 70
 Grooved Pegboard test, 95, 284, 285
 guidelines, 61, 131–133
 diagnosis/management of iNPH, 99, 232, 240
 Japanese, 99
 outcome assessment scales, 243
 Hakim’s triad, 91, 99, 232
 head circumference, posterior fossa cyst, 276
 head size, 15
 headache
 Chiari malformation and hydrocephalus, 277–278
 chronic shunting, 269, 270
 CSF leak surgery, 261
 early morning, 201–202

Index

- intermittent, spinal CSF leaks, 257
 low-pressure, 256–257, 270, 271
 positional, intracranial hypotension, 256–257, 259, 262
 posterior fossa cyst without hydrocephalus, 277
 pressure (supine), 261
 pseudotumor cerebri syndrome, 297
 slit ventricle syndrome, 269, 270
 spina bifida, management, 271
 hedgehog signaling, 45
 Hellström's grading scale, 92, 94
 herniation, 291
 cerebellar vermis, top, 292
 ETV complication, 226
 fourth ventricle, 293
 hindbrain, 291–292
 in myelography, 259
 hhy mouse, 40
 Hif-1 α , 47
 high pressure hydrocephalus, experimental, 31
 hindbrain herniation, 291–292
 histopathology, ventriculomegaly, brain damage, 15
 historical perspectives, 31, 304
 HIV/AIDS, 253
 HTX rat, 32, 33, 39, 46
 subcommissural organ development, 40
 Huntingtin (htt) protein, 44
 Huntington's disease, 72, 102
 hy1 mouse, 39
 hy2 mouse, 39
 hy3 mouse, 39–40, 44
 hydin (protein), 44–45
Hydin exons/mutants, 39, 45
 hydrocephalus, definition, 14
 hydrodynamic concept, iNPH, 220–221
 hydrodynamic resistance (shunts), *see* shunt(s)
 hydrophilic mice, 47
 hydrostatic pressure, 176
hyh gene, 40
hyh mouse, 40
 hypercoagulopathy, 300
 hypovascularization, 47
 hypoxic-ischemic stress/injury, 15, 23
 hysteresis, valves, 198
 idiopathic intracranial hypertension (IIH), 151, 296
 idiopathic NPH (iNPH), 14, 17, 91, 99, 207
 ApoE e3/e4 alleles and, 38
 autopsy findings, 18
 biomarkers, *see* biomarkers (CSF)
 cognitive defects, *see* cognitive impairment (in iNPH)
 definition, 304
 diagnostic guidelines, 99, 232
 epidemiology, 57–60, 104
 ETV in, *see* endoscopic third ventriculostomy (ETV)
 follow-up, 232, 243
 genetics, 38
 outcome, *see* outcome
 selection criteria for improved outcome, 232–233
 surgery frequency, 60–61
 symptoms, 232
 in elderly, 61, 100, 147
 as “two hit” disease, 240–241
Ift88 gene mutations, 45
 imaging, 103, 110–119, 304
 CSF pathologies with hydrocephalus, 285
 differential diagnostic role, 102–103
 modalities used, 110
 in PTCS, 298–299
 shunt assessment, 209, 210, 242
 immune response, changes, 47
 impaired executive function (IEF), 66, 73–74
 incontinence, *see* urinary incontinence
 infantile hydrocephalus, epidemiology, 57
 infections/infectious disease
 cognitive dysfunction due to, 102
 hydrocephalus after, 252–254
 shunt, *see* shunt infections
 inflammation, 31
 infusion techniques/tests, 103, 104, 141–144, 146, 147, 155–156
 bolus, 141–144, 146, 156
 brain atrophy and, 147
 Marmarou's model, 142, 144
 procedure, 142–143, 146
 results, 143
 bolus vs gradual, comparisons, 144, 146–147
 applications, 146
 baseline pressures and, 157–158
 R_{out} values, 157–158
 clinical prognostic applications, 146
 computerized infusion test, 155–156
 constant, 141, 144–145, 157
 gradual (steady-state), 144, 146, 156, 157
 constant flow, 144–145
 constant pressure, 145
 constant pressure constant infusion rate, 144–145
 herniation risk, 159
 intraventricular, 155–156
 periodic pulse pressure (CSF), 147
 principles, 141, 142
 shunt functioning assessment, 200–202
 slow waves, analysis, 158–159
 time-dependent pressure, responses, 141–144
 volume removal (bolus withdrawal), 143–144
 inheritance of hydrocephalus, 36–38
 INPH scale, 239, 240, 242–243
 β 8-integrin, 45
 interleukin-1 (IL-1), 166
 International Consultation on Incontinence Modular Questionnaires (ICIq), 84, 86
 International Hydrocephalus Imaging Working Group (IHIWG), 275, 287
 International Society of Hydrocephalus and Cerebrospinal Fluid Disorders (ISHCSF), 275, 287
 interstitial edema, NPH pathogenesis, 71, 72
 interstitial fluid, CSF production, 3, 5
 intracerebral hemorrhage, 114
 intracisternal obstructive hydrocephalus, ETV in, 221
 intracortical circuit defects, 67
 intracranial hemorrhage, ETV complication, 226–227
 intracranial hypertension
 active obstructive hydrocephalus, 159
 benign, 294–296
 Chiari I malformation and, 294–295
 cognitive impairment in iNPH and, 70–71
 idiopathic, 151, 296
 in morbid obesity, 294
 pseudotumor cerebri, 296, 298
 threshold, 298
 tolerance, 150
 transient, in ETV, 267
 ventricular enlargement failure, chronic shunts, 269
 intracranial hypotension, spontaneous, 256
 clinical presentation, 256–257
 positional headaches, 256–257, 259, 262
 diagnosis, three-step approach, 259–260
 diagnostic algorithm, 260
 diagnostic criteria, 259–260
 diagnostic imaging, 257–259
 outcome, 261–262
 pathogenesis, 256
 surgical treatment, 261
 treatment, 261–262
 see also cerebrospinal fluid (CSF), leaks

Index

- intracranial pressure (ICP), 139, 147
 baseline, 156–159
 bolus infusion technique, 141–143, 157–158
 brain atrophy, 159
 elevated, *see* intracranial hypertension
 fluctuations in cardiac cycle, 127, 128, 128, 152
 iNPH pathophysiology and ETV mechanism, 220–221
 measurements, 103, 298–299
 monitoring, 150–161, 283
 CSF flow changes, 128–129
 headaches in spina bifida, 271
 method, 152
 pediatric hydrocephalus, 155, 156
 prognostic biomarkers, 169
 pulse waveform, 152–154
 normal values, 103
 optimal, 152
 posture effects, 154
 pressure reactivity index (PRx), 155–156, 158–159
 pulse wave, in vivo shunt testing, 201
 pulse wave amplitude, 152, 153, 159
 peak-to-peak values, 154
 reference (P_0), 152, 191
 intracranial space, 1
 intracranial volume change (IVC), 128
 intraflagellar transport (IFT) genes, 44
 intraspinal tumors, 249–250
 intraventricular hemorrhage, 180, 218, 251
 ion channels, CSF turnover, 7–8
 IQ scores, 272
 isotope cisternography, 102
- kaolin, 46, 154
 experimental hydrocephalus, 31, 33
 Kiefer's Comorbidity Index, 94, 96
 Kocher's point, 177
 Krauss's classification, 91, 93
 Kruppel-like factor 4 (KLF4), 47
 Kubo's grading scale, 92, 94
- L1CAM* gene, 36, 38
 lactate, 166
 lamina terminalis, fenestration, 252
 late-onset idiopathic aqueductal stenosis (LIAS), 247–248
 lateral ventricles, 1
 anatomy, 2
 cellular composition, 5
 CT imaging in NPH, 110
 frontal horns, 111
 hydrocephalus pathophysiology, 292
 occipital horn, 2
 temporal horn, 2, 110, 113
 tumors, 249
- volume reduction after ETV, 222
 leptomeningeal spread, cancer, 102, 250
 leucine-rich repeat kinase 2 (LRRK2), 168
 leucine-rich α 2-glycoprotein (LGR), 169
 LEW/Jms rat model, 39, 44
 Lewy body disease, 101, 102
 LOTTA® rod-lens ventriculoscopic system, 224
 LOVA (longstanding overt ventriculomegaly in adults), 100, 247–248, 283
 low-pressure syndromes, 256–262
see also cerebrospinal fluid (CSF), leaks; intracranial hypotension, spontaneous
 lower urinary tract symptoms (LUTS), *see* urinary tract symptoms
 lumbar catheter insertion, 183–185
 lumbar puncture, 259
 multiple, 300–301
 pseudotumor cerebri syndrome, 298–301
 lumbar stenosis, 101, 185
 lumboperitoneal shunt insertion, 184, 192
 complications, in PTCS, 301
 contraindications, 270
 indications, 249
 in normal volume hydrocephalus, 270
 lumbopleural shunt, in PTCS, 301
 lymphatic drainage, 9–10
- macrophage, activation, 47
 magnetic fields, effect on valve settings, 199–200
 magnetic resonance angiography, time-of-flight, 121
 magnetic resonance imaging (MRI), 103, 114–117
 advantages and preferred sequence, 114–115
 cardiac gating, 121–122
 CSF flow studies, 121–124
 CSF leak, 257–259
 CSF pathologies with hydrocephalus, 285
 CSF spaces, 285
 diagnosis of NPH, 115, 116
 disadvantages, 115
 ETV, 223–224
 gadolinium enhancement, 117, 118
 NPH differential diagnosis, 103
 phase-contrast (“*cine*”), *see* phase-contrast MRI (PC-MRI)
 pseudotumor cerebri syndrome, 298
 shunt complications, 209, 210
- signal to noise ratio (SNR), 123
 spinal, CSF leaks, 259
 supra/infratentorial meningeal enhancement, 257
 ventricular catheter insertion, 179
 ventriculomegaly detection before symptom triad, 100
 volumetric analysis by, 113
 malignancies, and hydrocephalus, 248–251
 mammillary body, 224
 management, of congenital hydrocephalus in adults, 264–273
 chronically shunted patients, 269–271
 strategies, 270–271
see also slit ventricle syndrome
 difficulties, 264
 outcomes, 271–273
 clinical, 271–272
 neuropsychological, 272–273
 shunt independence, 267–269
see also endoscopic third ventriculostomy (ETV)
 transitioning neurosurgical care, 264–267
 adolescents and hybrid models, 265
 adult neurosurgery perspective, 265–266
 cognitive impairment impact, 265, 266
 difficulties, 265
 dual-role care model, 265
 lack of guidelines, 266
 multidisciplinary care, 264–265, 266–267
 patient/family perspective, 266
 pediatric perspective, 265
 plan/documentation, 266
 recommendations, 266–267
 management, of hydrocephalus in CSF pathologies, 275–287
 case studies, 283–284
 cerebellar arachnoid cyst with NPH, 279–280, 283
 Chiari I malformation and NPH, 277–278, 279, 283
 giant suprasellar arachnoid cyst (fetal), 282
 multiple arachnoid cysts, 281
 posterior fossa cyst, 276–277, 278, 283
 cognition/cognitive assessment, 284–285
 decision-making, 283–284
 disease classification role, 286–287
 multimodal surgery, 285–286
 neuroimaging and MRI role, 285

Index

- Marfan syndrome, 256
 Marmarou, Professor Anthony, 80–88, 287
 Marmarou's model/theory, 139–141, 142, 144, 151–152, 190
 bolus infusion, 142, 144
 pressure/flow linear relationship, 145
 Marmarou's monoexponential function, 128
 Mdnah5 protein, 45
 memory deficits, iNPH, 74, 76
 meningitis, 252–253, 268
 carcinomatous, 249
 mental status evaluation, extended, 73
 mesencephalic locomotor region (MLR), 64–65
 metabolic diseases, cognitive dysfunction and, 102
 “Mickey Mouse” ventricles, 111
 micturition, 82, 83
 midbrain
 compression/atrophy, gait dysfunction, 64–65
 diameter, gait defects and, 64, 65
 volume loss, chemical/mechanical mechanisms, 65
 mini-mental state examination (MMSE), 101
 MOMs trial, 286
 monoamine neurotransmitters, 23
 Monroe–Kellie doctrine, 10, 291–292
 motor cortex, aberrant circuits, 67
 motor skill impairment, 75, 76
 Msi1 (Musashi 1), 44
 MSM mouse strain, 40
 Mx1 gene, 44
 Mtf2 and Mtf2 mutants, 45
 myelography, CSF leaks, 259, 260
 myelomeningocele, 294
 neonates, post-infective hydrocephalus, 252
 neural tube defects, 46–47
 neurochemical disturbances, 71
 neurocysticercosis, 253–254
 neurodegenerative diseases
 biomarkers (CSF), 164
 cognitive dysfunction, 72
 gait dysfunction, 64–66, 100–101, 167
 neurofilament protein (NFL), 167, 169
 neurological examination, 99–100
 neuronal death, 23
 neurons, altered connections, 23
 neuropathology (of hydrocephalus), 14–23
 immature/young animals as model, 14
 see also ventricular enlargement
 neuropsychological deficits (in iNPH), 72
 Alzheimer's disease comparison, 74
 comorbidities, 76, 77
 differential diagnosis, 76–77
 localization, 73–75
 response to CSF drainage, 75–76
 see also cognitive impairment (in iNPH)
 neuropsychological examination (in iNPH), 72, 73, 95, 239, 284–285
 neuropsychological outcomes, in chronic shunting, 272–273
 neurotransmission, disturbances, 71
 nocturia, 85
 non-canonical Wnt pathway, 45
 noncommunicating hydrocephalus, *see* obstructive (noncommunicating) hydrocephalus
 nonobstructive hydrocephalus, *see* communicating hydrocephalus
 nonsyndromic hydrocephalus, 36, 38
 see also congenital hydrocephalus
 nonverbal learning disabilities syndrome, 272
 normal pressure hydrocephalus (NPH), 14, 91, 304
 definition, and terminology, 131, 139
 see also specific aspects/topics
 normal volume hydrocephalus (NVH), 265–266, 270
 treatment, 270
 obesity
 Chiari I malformation and pseudotumor, 294
 PTCS and, 294, 300, 301
 obstructive (noncommunicating) hydrocephalus, 159, 190, 218, 292, 304
 brain tumors and, 248–249
 CSF dynamics, 159
 ETV in, *see* endoscopic third ventriculostomy (ETV)
 intraventricular and extraventricular, 220
 octreotide, 300
 opening pressure, *see under* shunt(s)
 OPHN1 (oligophrenin 1) protein, 46
 optic nerve sheath fenestration, 301
 organ failure, 102
 ouabain, 8
 outcome (of iNPH), 200, 232–245
 case study, 106
 comorbidities impact, 244
 congenital hydrocephalus, 271–273
 deficiencies in impairment identification, 233–240
 grading, *see* grading scales (NPH)
 difficulties in assessing, 232
 pre-/postoperative score comparison, 240, 242
 prediction
 comorbid diseases, 244
 CSF dynamics, 159
 ELD use, 233
 neurocognitive tests, 284–285
 preoperative factors, 244
 R_{out} role, 157–158
 shunt independence, 269
 see also shunting, patient selection
 publications (summary), 234
 selection criteria for iNPH diagnosis, 232–233
 shunt complications impact, 244, 271–272
 standardized management protocols, 240–243
 clinical judgment and, 243
 outcome assessment (standardized), 242–243
 shunt management, 240–242
 time period, short/long term, 243
 valve selection/use, 241
 by symptoms, 232, 242
 outcome scales, 242
 overdrainage (shunting), 175–176, 190, 208–209
 causes, 199, 201
 differential pressure valves, 192
 lumbar catheter placement, 185
 management and assessment, 208–209
 MRI, 209
 postural, 201
 rates, 211
 slit ventricle syndrome, 270
 symptoms, 208, 270
 p57 gene, 44
 PAC1 receptor, 47
 Pacrg (Parkin-coregulated gene), 45
 pad tests, 81
 Parkinsonism, 17, 58, 167
 Parkinson's disease, 167–169
 cognitive dysfunction, 72
 gait and executive function impairment, 66, 100–101
 Pascal's law, 125
 pathology, *see* neuropathology (of hydrocephalus); ventricular enlargement
 pathophysiology, 36
 Chiari I malformation and hydrocephalus, 292

Index

- pathophysiology (*cont.*)
 Chiari II malformation and
 hydrocephalus, 292–294
 hindbrain herniation role, 292
 hydrocephalus in intraspinal
 tumors, 250
 late-onset idiopathic aqueductal
 stenosis, 247
 pseudotumor cerebri syndrome,
 299–300
 urinary incontinence, *see* urinary
 incontinence
 pathophysiology (of iNPH), 70
 abnormal brain development, 48
 cognitive defects, *see* cognitive
 impairment (in iNPH)
 gait dysfunction, *see* gait dysfunction
 in NPH
 putative pathogenic mechanisms,
 70–72, 220–221, 240–241
 cerebrovascular compromise,
 71, 72
 hyperdynamic CSF flow, 71, 133
 interstitial edema, 71, 72
 mechanical distortion, 70
 neurochemical disturbances, 71
 pressure effects, 70–71, 220–221
 synthesis of mechanisms, 72,
 220–221, 240–241
 toxin accumulation, 71, 72
 pathophysiology, genetic basis, 40–48
 enhanced expression of genes, 47–48
 immune response changes, 47
 molecular cue loss during
 development, 40–46, 47
 neural tube defects, 46–47
 unknown causes (mouse lines), 47
 see also genes/loci
 pax6, 44
 PC-MRI, *see* phase-contrast MRI
 (PC-MRI)
 Pcdp1 (primary ciliary dyskinesia
 protein 1), 45
 pediatric psychologists, 267
 pedunculopontine nucleus (PPN), 65
 peptide transporters, choroid plexus, 5
 peripheral neuropathy, 101
 peritoneal catheter insertion, 178, 180
 complications, and variations,
 180, 209
 procedure, 177, 180
 see also ventriculoperitoneal shunt
 phase-contrast MRI (PC-MRI), 115–117
 acceleration methods, 122
 aliasing correction, 124
 aqueductal stenosis, 130–131, 247
 cautions/limitations, 131
 cerebral venous flows, 133
 CSF and blood flow interactions,
 125–129, 133
 healthy adults, 126, 128
 CSF flow, 121, 125
 after ETV, 131
 CSF disorders, 129–134
 before ETV, 223–224
 CSF flow parameters, 124, 125
 diagnosis of NPH, 131–133
 ICP changes during cardiac
 cycle, 128–129
 late-onset idiopathic aqueductal
 stenosis, 247
 parameters affecting quality/
 accuracy, 122–123
 parameters summary, 122
 phase encoding, 122
 post-processing and software,
 123–125
 principle and gray scale, 121, 122
 quantitative *vs* qualitative, 122
 questions to ask, 123
 study results, 123, 124
 temporal normalization, 124
 pineal gland, “spiritus animalis” dogma
 and, 31
 pituitary hyperemia, 257–258
 planar cell polarity (PCP) signaling, 45
 plethysmography, 121–122
 pleural catheter insertion, 181–183
 complications, 176, 182
 Polaris valve, 196
 PolL (DNA polymerase λ), 45
 polycystin-1 (PC-1) protein, 45
 pontine micturition center, 82
 post-infective hydrocephalus, 252–254
 posterior fossa anomalies, 291
 classification, 286–287
 posterior fossa cyst, 277, 278
 hydrocephalus with, 276–277, 283
 postoperative care, 176–177
 postural control, 63, 67
 postural instability, gait dysfunction
 due to, 67
 posture, 154
 differential-pressure valves, effect
 on, 192
 headache in intracranial
 hypotension, 256–257, 259, 262
 lumboperitoneal shunts, 192
 postural overdrainage, 201
 siphoning and, 191
 predictive validity, animal models, 29
 prenatal surgery, 286
 preoperative planning, ETV, 222–224
 preoperative preparation, 176–177, 186
 presenilin-1 (PS-1) gene, 38, 44
 pressure–flow performance (of shunts),
 195, 198–199
 pressure–flow test, 195, 197
 pressure reactivity index (PRx), 155–
 156, 158–159
 pressure–volume compensation,
 150–152, 190
 pressure–volume compensatory
 reserve, 155, 158–159
 pressure–volume curve, 152
 see also Marmarou’s model/theory
 pressure–volume index (PVI), 139–
 140, 142, 143, 147, 158
 presymptomatic stages of NPH,
 threshold effect, 15
 preterm infants, post-infective
 hydrocephalus, 252
 primary ciliary dyskinesia, 46
 ProGav valve, 196
 progressive supranuclear palsy
 (PSP), 102
 protein, CSF, 1
 pseudomeningocele, 277, 292, 294
 pseudotumor cerebri (PTC)
 Chiari I malformation and, 294–295
 lumbar catheter insertion
 complications, 185
 lumbar *vs* ventricular
 catheterization, 185, 301
 overdiagnosis, 294
 pathophysiology, 291
 pseudotumor cerebri syndrome
 (PTCS), 296–302
 associated conditions, 297–298
 in children, 297
 clinical features, 297
 Dandy criteria, 296–297
 history, 296
 investigations, 298–299, 300
 in males, 297
 management, 300–302
 medical, 300–301
 in obesity, 294, 300, 301
 surgical, 301–302
 thin patients, 294–295
 nomenclature, 296
 NPH *vs*, 296
 pathophysiology, 299–300
 psychologists, pediatric, 267
 psychomotor dysfunction,
 localization, 73–74
 ptch1 deficiency, 45
 putamen, dorsal, 68
 pyogenic infections, 252–253
 pyramidal tracts, gait dysfunction, 63
 quantitative trait locus (QTL), 39
 radiation therapy, hydrocephalus
 after, 249
 radionuclide cisternography, 259
 radionuclide shunt patency test,
 118–119
 Rankin Scale, modified, 91, 92, 242
 RAP index, 155

- RAVLT (Learning and Delayed Recall test), 285
 recurrence risk ratios (RRRs), 37
 reduction principle, animal models, 28–29
 reference pressure (P_0), 152, 191
 refinement principle, animal models, 29
 relative replacement principle, 28
 replacement principle, animal models, 28
 RFX3 (regulatory factor X3), 44
 RFX4 (regulatory factor X4), 44
 rhinorrhea, CSF, 297
 Rickham reservoir use, 179–180
 rodents, 30, 32
 rostral tumor cyst, 250
 R_{out} (CSF outflow resistance), 103, 151, 154, 158, 283
 bolus vs steady-state infusion, 157–158
 cerebral autoregulation and, 159
 elevation, 156, 159
 physiologic, 157
 pressure reactivity (PRx) and, 158
 shunt improvement prediction, 156–158
 sagittal sinus pressure (P_{ss}), 133, 151, 269, 299, 300
 CSF pressure relationship, 299, 300
 secondary NPH (sNPH), 14, 17, 91, 247–254
 after brain tumors, 248–251
 after infections, 252–254
 after spinal cord tumors, 249–250
 after subarachnoid hemorrhage, 251–252
 causes, 248
 epidemiology, 60
 R_{out} (CSF outflow resistance), 158
 surgery frequency, 60–61
 urinary incontinence, 85
 senile plaques, 16, 17
 shunt(s), 190–205
 closing pressure, 196
 distal pressure, 201
 effective operating pressure, 201
 future prospects, 204–205
 hardware, 192–194
 see also antisiphon devices; valves (shunts)
 hydrodynamic parameters tested, 191–192
 hydrodynamic properties, 196–200
 hydrodynamic resistance, 196, 199
 long distal catheters, 199
 low, overdrainage, 201–202
 specific shunts, 193
 ventricular catheters, 199
 ideal, 190
 imaging/assessment, 209, 210, 242
 long-term, CSF hydrodynamics, 269
 management standardization, outcome, 240–242
 negative outlet pressure, 199
 operating (opening) pressure, 118, 196, 199, 201
 specific valves, 200
 patency testing, *see* shunt testing
 proximal pressure, 200
 recent developments, 192
 removal, severe slit ventricle syndrome, 270
 revision, risk identification, 271
 role/aims, 190
 temperature effect, 200
 types, hydrodynamic resistances, 193
 see also shunt procedures; shunting; *specific shunt types*
 shunt complications, 204, 207–215
 catheter migration, 209
 imaging, 209, 210
 impact on outcome, 244, 271–272
 major/minor, 244
 prevention, improved outcome, 244
 rates, 209–212, 244
 treatment of, 244
 types, 208, 211
 see also shunt infections; shunt malfunction
 shunt failure, 208, 304
 ETV after, 219–220
 rate, 190, 211
 symptoms, 213
 shunt independence, 267–269
 monitoring/evaluation, 267
 see also endoscopic third ventriculostomy (ETV)
 shunt infections, 185–187, 212–215
 causative organisms, 185–186, 213–215
 costs and hospital stay duration, 187
 diagnosis, 213
 frequency, and timing, 185
 mechanisms and causes, 212–213
 rates, 209–210, 212
 adult vs children, 212
 secondary ETV outcome, 268
 sequelae, 212, 213
 shunt insertion protocol to reduce, 186
 symptoms, 209, 213
 treatment/preventative strategies, 213–215
 antibiotic management, 186–187
 see also antibiotic-impregnated shunts (AIS)
 shunt malfunction, 190, 271–272
 adjustable valve use to reduce, 241
 blocking by particles, 200
 catheter tip obstruction, 179
 in chronically shunted patients, 265–266, 271–272
 CT detection, 113–115
 diagnosis, 200, 242
 ETV after, 268
 imaging, 242
 incidence and outcome, 271–272
 obstruction, lumbar catheter, 185
 outflow resistance, infusion tests, 146
 radionuclide detection, 118–119
 site, evaluation, 118
 ventricular catheter, 178
 VP shunts, frequency, 271
 X-ray detection, 110, 111, 112
 shunt outcome, *see* outcome
 shunt procedures, 175–187
 closure techniques, 177
 for communicating hydrocephalus, 185
 distal catheter insertion, 180–183
 resistance increase, 199
 see also specific catheter types
 general surgical principles, 176–177
 hardware, 192–194
 lumbar catheter insertion, *see* lumbar catheter insertion
 optimal settings, 175–176
 planning, duplex ultrasound, 110, 112
 postoperative care, 176–177
 protocol to reduce infections, 186
 proximal catheter placement, 177–180
 see also ventricular catheter insertion
 shunt registry, 202–204
 shunt testing
 in vivo, 190, 200–202
 laboratory, 194–197
 radionuclide, 118–119
 shunt valves, *see* valves
 shunting
 cognitive response, *see* cognitive impairment (in iNPH)
 evaluation, X-rays, 110
 experimental hydrocephalus, 33
 follow-up, 207–215
 frequency in iNPH and sNPH, 60–61, 104
 gait improvement, 63, 64, 73, 88
 dual-tasking and cognitive function, 66
 increased regional CBF, 68
 intracortical circuits and, 67
 midbrain diameter and, 64, 65
 incontinence improvement, *see* urinary incontinence

Index

- shunting (*cont.*)
 indications, 190
 outcome, *see* outcome
 overdrainage, *see* overdrainage (shunting)
 as “patch” not cure, 30
 patient selection, 190, 207, 210, 215
 CSF dynamics role, 159
 for improved iNPH outcome, 232–233
 tests for, 103, 146
 see also outcome (of iNPH), prediction
 pseudotumor cerebri syndrome, 301
 response prediction, 16, 165
 risk-to-benefit ratio, 207–208, 215
 underdrainage, 175–176, 208
 white matter changes, 16
see also shunt(s); shunt procedures
 “shuntogram”, 118
 SHYMA (syndrome of hydrocephalus in young and middle-aged adults), 247–249
 SINPHONI study, 233, 244
 siphoning (CSF) into distal compartment, 176
 devices to prevent, *see* antisiphon devices (ASD)
 siphoning pressure, 191
 slit ventricle syndrome (SVS), 192, 202, 294
 characteristics, 269
 CSF overdrainage, 270
 definitions, 269
 management, 269–271
 severe classical form, 271
 shunt removal in, 270
 slow waves, 154, 158–159
 α -SNAP, 40
 social development, 272–273
 SOCS7, 47
 sodium-potassium-ATPase pump, 7, 8
 soluble amyloid precursor protein (sAPP), 166, 168, 169
 “solute-coupled” transport, 8
 somatostatin-like
 immunoreactivity, 168
 sonic hedgehog (Shh) signaling, 45
 Sophy Adjustable valve, 194, 196, 199–200
 Sox3, overexpression, 47
 special healthcare needs (SHCN), 264–267
 sperm associated antigen 6 (Spag6), 45
 spina bifida, 292, 294
 ETV outcome, 268
 headache management, 271
 neuropsychological impairment, 272
 prenatal repair, MOMs trial, 286
 shunt dependency, 294
 spinal central canal, CSF flow, 6
 spinal cord tumors, 249–251
 spinal CSF anatomy, 3
 spinal lymphatic drainage, 9–10
 spinal tap test (STT), 103, 104, 145–146
 method, and outcome evaluation, 146
 Stein–Langfitt classification, 91, 92, 242
 steroid metabolism, 300
 Strata valve, 196, 202
 stroke, 244
 stroke volume, CSF, 124, 125, 128, 133, 285
 stroke volume ratio, 133
 Stroop Color Word Test, 73, 75, 95, 239, 284, 285
 Stumpy mouse, 46
 subarachnoid cisterns, *see* cisterns (subarachnoid)
 subarachnoid hemorrhage (SAH)
 CSF movement impairment, 14
 ETV complication, 226–227
 hydrocephalus after, 251–252
 acute, 251
 subacute and chronic, 251–252
 subarachnoid space (SAS)
 arachnoid granulations, 8–9
 cortical, in PTCS, 296
 CSF flow, 5, 127
 poor, Chiari II malformation and, 293
 DESH, 99, 115, 117, 233, 304
 enlargement, 14
 leaky epithelium, 8
 obstruction, 99, 102, 292
 spinal, CSF flow, 6
 volumetric analysis by CT/MRI, 113
 subcommissural organ (SCO), 40
 abnormal development, 40–44
 defects, proteins/factors involved, 40–44, 46, 47
 subcortical vascular dementia, 101, 167
 subdural fluid collection, 257, 258
 subdural hematoma (SDH), 102, 211, 227
 subdural hygroma, 114, 115, 211
 substantia nigra, damage, 71
 subtemporal decompression, 301
 sulfatide, as biomarker, 167
 superior sagittal sinus
 narrowing, 299, 300
 pressure, *see* sagittal sinus pressure (P_{ss})
 suprasellar arachnoid cyst, giant, 282
 supraspinal pathways, micturition control, 82–83
 surgery
 CSF leak management, 261
 minimally invasive, 286
 multimodal, 285–286
 shunt, *see* shunt procedures; shunting
 Sylvius, cerebral aqueduct, *see* cerebral aqueduct (of Sylvius)
 symbol digit modalities (SDMT), 73, 75, 76
 symptoms, of NPH, 63, 91, 92, 99
 classification based on, 104
 duration, outcome affected by, 76, 100
 early to progressive stages, 72–73, 104
 grading scales, *see* grading scales (NPH)
 Hakim's description, 91, 99, 232
 ventriculomegaly detection before, 100
 see also cognitive impairment; gait dysfunction in NPH; urinary incontinence
 syndrome of hydrocephalus in young and middle-aged adults (SHYMA), 247–249
 syndromic hydrocephalus, 36
 syringomyelia, 135
 $T_{1/2}$ time, 118
Taenia solium, 253–254
 tanocytes, 5
 tap test, *see* spinal tap test (STT)
 tau protein
 in Alzheimer's disease, 165
 as iNPH biomarker, 164, 168, 169
 Alzheimer's disease vs, 165, 166
 prognostic marker, 168, 169
 vascular dementia vs, 167
 in Parkinson's disease, 168
 phosphorylated (p-tau), 165, 168, 169
 tauopathy, 102
 temperature, shunt functioning, 200
 ten-meter walk test, 92, 100
 tension hydrothorax, 182
 Texas strain, rat model, *see* HTX rat
 thalamoatriate vein, 2
 third ventricle, 1
 anatomy, 2
 cellular composition, 5
 dilatation, gait dysfunction, 63
 obstruction, MRI, 114
 volume reduction after ETV, 222
 tight junctions, 4
 timed up and go test (TUG), 92, 100
 tinnitus, 297
 topiramate, 300
 torcula position, and compression, 293–294
 toxin accumulation, reduced CSF production, 71, 72
 toxoplasmosis, 253

Index

- Trail Making tests, 73, 76
 transcranial Doppler-derived pressure
 autoregulation, 159–160
 transferrin, isoforms, 166
 $\beta 2$ -transferrin, 1
 transforming growth factor- $\beta 1$
 (TGF- $\beta 1$), 32, 48
 transgenic animals, 32
 OVE459 mouse line, 39–40
 TGF- $\beta 1$ overexpression in mice,
 32, 48
 traumatic encephalopathy, chronic, 102
 triventricular hydrocephalus, ETV
 in, 222
 twin studies, 36–37
- UK Shunt Evaluation Laboratory, 194
 UK Shunt Registry, 204
 ultrasonography, 110, 112, 181
 uncomplicated hydrocephalus, 36
 underdrainage (shunting),
 175–176, 208
 upper limb motor control, 63
 urinary incontinence, 80–88
 caregiver distress, 80, 85
 definition, 80, 81
 in dementia, 80–81
 differential diagnosis, 102
 etiologic theories, 82
 evaluation, 92, 240, 242
 grading scales, 92, 95, 240
 see also urinary tract
 symptoms
 measurement, 81
 pathophysiology, 82–83, 86
 prevalence and significance, 80,
 81, 85
 secondary NPH, 85
 shunting, outcome, 85–87
 stress, 82, 86
 treatment, 87–88
 urge, 85
 urologic history, 83
 urinary sphincter, 82
 urinary tract function, normal, 82
 urinary tract symptoms, 80–88, 102
 characterization, 85–86
 Virginia Commonwealth
 University, 85–87
 differential diagnosis, 81–82, 102
 in elderly, 82
 evaluation, 83–85, 92
 diagnostic testing, 84
 examination, 84
 urodynamic testing, 84–85
 urologic history, 83
 validated questionnaires, 83–84,
 86, 240
 grading scales, *see* grading
 scales (NPH)
- incontinence, *see* urinary
 incontinence
 pathophysiology, 63, 82–83, 85
 post-void, 83
 prevalence, 85
 shunting effect, 85–88
 SHYMA, 248
 storage (irritative), 81, 83
 terminology, 83
 types, 81
 urinary frequency, 85
 urinary urgency, 81, 85
 voiding (obstructive), 81, 83
 urodynamic testing, 84–85
- VACTERL with hydrocephalus, 37
 valves (shunts), 175–176, 194, 198
 active, future prospects, 204
 adjustable, 175, 176, 192–194
 comparisons, 196
 magnetic field effect, 199–200
 outcome improvement, 241
 re-setting, 199, 244
 antisiphon, 175, 176
 ball on spring, 194, 198
 differential pressure, 175, 176, 192,
 201, 241
 complications, 192
 long distal catheters,
 resistance, 199
 position effect, 192
 principles, 192
 flow-regulated, 175, 176, 194, 204
 horizontal-vertical, 175
 hydrodynamic resistances,
 542/110, 193
 overdrainage, 201–202
 types, outcome improvement, 241
 vascular dementia, 101, 167
 vasoactive intestinal peptide (VIP), 167
 vasopressin, 166
 V_{enc} (velocity encoding parameter),
 122, 131
 venous sinuses, CSF flow, 9
 venous stenting, in PTCS, 301–302
 ventral dural tears, 261
 ventricles, 3
 anatomy, 2, 32
 cellular composition, 5
 CSF flow, 5
 size, ETV selection, 222–223
 see also specific ventricles
 ventricular catheter insertion,
 177–180
 antisiphon device use, 176
 catheter tip obstruction, 179
 children, closed fontanelles, 179
 complications and advice, 178–180
 endoscopic visualization, 179
 frontal approach, 177, 178
- lumbar catheterization *vs.*, 184–185
 parieto-occipital approach, 177, 179
 procedure, 177–180
 pseudotumor cerebri syndrome, 301
 resistance, 199
 stereotactic guidance, 179
see also ventriculoperitoneal shunt
 ventricular enlargement, 14
 asymptomatic, 15, 104
 prevalence, 104
 white matter changes, 16
 consequences, 15
 altered neurons/connections, 23
 atrophy and brain damage, 15
 autopsy findings, 17, 18
 blood flow reduction, 15, 23
 extracellular fluid changes, 16
 fornix and corpus callosum
 atrophy, 15, 17
 secondary reactive changes, 23
 white matter changes, 15–17
 factors leading to, 14–15, 220–221
 failure, in slit ventricle syndrome,
 269–271
 see also slit ventricle syndrome
 increased ICP pulse amplitude, 153
 measurement, CT, 110–113
 pathophysiology,
 see pathophysiology (of iNPH)
 rate, 23
 threshold effect for tolerance to, 15
 ventricular system, 1
 ventriculoatrial shunt, 182, 207
 see also atrial catheter insertion
 ventriculomegaly, *see* ventricular
 enlargement
 ventriculoperitoneal shunt, 207, 271
 brain tumors, 249
 Chiari I malformation with
 hydrocephalus, 278
 Chiari I malformation with
 pseudotumor, 294–295
 complication rate, 209–212
 complications, 210–212, 271
 CT, 114, 116, 209
 ETV *vs.*, 222
 insertion, 178
 risks, 210
 see also peritoneal catheter
 insertion; ventricular catheter
 insertion
 ventriculopleural shunt insertion, 183
 ventriculostomy
 catheter placement/removal, 180
 ETV, *see* endoscopic third
 ventriculostomy (ETV)
 hydrocephalus after subarachnoid
 hemorrhage, 252
 verbal memory, 74
 vestibular schwannoma, 60

Index

Virchow–Robin spaces, 6	<i>see also specific aquaporins</i>	<i>Wnt</i> signaling, 45, 47
visual memory, 74, 76	weight, experimental animals, 29	Wnt1 cell lineage, 44
visual symptoms, in PTCS, 297	white matter	word list learning tasks, 74
visuospatial skills, 74–76, 272	cerebral blood flow reduction, 160, 161	
void diaries, 81	in NPH, 15–17, 74, 101	X-linked inheritance, 37
volume removal (bolus withdrawal), 143–144	distortion and cognitive defects, 70	X-rays, 110, 111
	outcome of shunting, 240	shunt assessment, 177, 209
water	Windkessel effect, 10, 153, 154	
CSF production, 4, 7, 8, 14	winged helix family, transcription factors, 45	Zarit Caregiver Burden Scale, 94
distribution in brain, 1	Wistar-Lewis rat model (LEW/Jms), 39, 44	<i>Zic5</i> gene, 47
“solute-coupled” transport, 8		zona adherens, 5
water channels, deficient, 46		zona occludens, 4